Sara Shahhosseini

Sara Shahhosseini

Auto-generated profile, based on publicly available information

Sara Shahhosseini

Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Iranian South Medical Journal
Verified
Journal Article
Open access
PDF file
SSSara Shahhosseini
Sara Shahhosseini
MZMaryam Zare
Maryam Zare
Background: Asthma is a common inflammatory disease of the airways which is characterized by variable and recurrent symptomes. The disease causes airways inflamtion and hyperresponsiveness, reversible airways obstruction and airway deformity and accomponied with symptoms including shortness of breath, cough and wheezing in patients. Environmental and genetic factor such as gene ...

25 December 2023 in Journal of Lab Animal Research
Verified
Journal Article
Open access
PDF file
AHAhmad Mir Hosseini
Ahmad Mir Hosseini
SDShiva Dianaty
Shiva Dianaty
SSSara Shahhosseini
Sara Shahhosseini
RBReza Biglarifard
Reza Biglarifard
RRRazieh Razmi
Razieh Razmi
DSDanial Soltani
Danial Soltani
Background/Objective: Leukemia, a heterogeneous group of blood cancers, can present a significant clinical challenge due to its varying subtypes and complexity. The application of nanotechnology has the potential to revolutionize the treatment of leukemia. Based on in vivo studies, this systematic review provides an accurate and current assessment of nanotechnology therapeutic advances in leukemia treatment. Methods: The present systematic review focused on in vivo studies investigating nanotechnology's therapeutic potential for leukemia treatment. Comprehensive searches were conducted across leading databases, including PubMed, Scopus, and Google Scholar, to identify relevant publications. Selection criteria encompassed studies that employed animal models to assess nanotechnology effects on leukemia progression. Data extracted from selected articles were rigorously analyzed. This review included studies published between 2010 and 2022. Results: Based on the inclusion criteria, 24 relevant studies were identified. According to the findings of this review, nanotechnology has made substantial progress in the treatment of leukemia, as demonstrated by in vivo studies. Advanced nanoparticle-based drug delivery systems, precision gene therapies, and targeted therapeutic approaches have consistently exhibited superior outcomes in treating various leukemia subtypes in animal models. These compelling results emphasize the transformative potential of nanotechnology for leukemia therapy. Conclusion: In conclusion, the meticulous analyses of the in vivo studies underscore the role that nanotechnology plays in the advancement of the treatment of leukemia. Nanotechnology has demonstrated efficacy in preclinical models, indicating that it can be translated into clinical applications, offering new avenues for treating leukemia and reinforcing its position as an innovative therapeutic approach.